Takeda Pharmaceutical Stock - Annual report filed and analyst consensus steady
17.06.2026 - 22:28:08 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 20:20 UTC. Details in the imprint.
Takeda Pharmaceutical (US8740602052) has recently detailed its balance sheet and key risks in its latest annual report on Form 20-F, according to a SEC filing summary. Wall Street, meanwhile, continues to rate TAK as a Moderate Buy based on current consensus data.
All news and key data on Takeda Pharmaceutical stock
Background, filings and price data on Takeda help investors understand how the Japanese pharma group positions itself on the NYSE via its ADR.
What the latest filing shows
In its most recent Form 20-F for foreign issuers, Takeda outlines total debt of about JPY 4.88 trillion and highlights restructuring costs following earlier acquisitions, according to a SEC filing summary based on the annual report.
The filing also draws attention to upcoming patent cliffs and pricing pressure for key drugs such as Entyvio and Trintellix, underscoring how future revenue growth depends on replacing these cash flows with new products.
Consensus view on TAK today
Analyst data compiled by MarketBeat shows Takeda Pharmaceutical ADR carries a consensus rating of Moderate Buy, with the stock recently quoted around $15.64 at the close on 06/16/2026.
Extended trading quotes indicate modest activity outside regular hours, with the ADR last indicated near $15.66 in pre-market dealing on 06/17/2026.
How the company makes money
Takeda is a global research-driven biopharmaceutical group focused on prescription medicines for oncology, rare diseases, neuroscience and gastroenterology. Flagship products include inflammatory bowel disease therapy Entyvio and antidepressant Trintellix, alongside a growing pipeline of specialty drugs.
Where the stock trades today
The shares of Takeda Pharmaceutical (US8740602052) trade on the New York Stock Exchange as an ADR under the ticker TAK, last quoted at about $15.64 as of 06/16/2026, 15:59 Eastern Time.
Key facts on Takeda Pharmaceutical stock
- Company: Takeda Pharmaceutical Company Limited
- ISIN: US8740602052
- WKN: 853849
- Ticker: TAK
- Venue: NYSE (ADR)
- Price (as of 06/16/2026, 15:59 ET): 15.64 USD
- Market cap: 49.01 billion USD (as of 06/16/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: Takeda stock is part of major Japanese indices such as the TOPIX via its primary Tokyo listing, while the TAK ADR provides US investors access.
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
